Welcome to

NOK Therapeutics

We are a clinical-stage biotechnology company pioneering a new paradigm in cancer care: safe, practical, and timely natural killer (NK) cell therapies. 

Welcome to

NOK Therapeutics

We are a clinical-stage biotechnology company pioneering a new paradigm in cancer care: safe, practical, and timely natural killer (NK) cell therapies.

Our Mission &

Vision for the Future

Our mission is simple yet ambitious: to restore the body’s first line of immune defense at the moments when patients need it most.

Vision: To normalize this new category of immunotherapy – cell therapies designed for the precise therapeutic moments when cures are within reach.

NOK's Approach

Filling the Critical Gap in Oncology

NOK Therapeutics was founded to fill a critical gap in oncology with autologous, non-engineered NK cell therapies designed to extend remission, expand access, and integrate seamlessly into standard cancer care.

Addressing Relapse

Our NK cells are designed for patients who relapse despite aggressive frontline therapy.

Expanding Access

Many are excluded from cell therapies due to toxicity, cost, or logistics – our NK cells fill this critical gap.

Seamless Integration

Our NK cell therapies are designed for practical use with outpatient infusions and flexible re-dosing highly feasible.

Led by Industry Veterans

Leadership with combined 50 years in pharmaceutical development and involvement in 45+ FDA approvals.

Robert Lewis

CEO

Operational leader with 30 FDA approvals and commercialization expertise.

Full Bio

Tamara Jovonovich, PhD

COO

Strategic scientist integrating experience in research and leadership to advance novel therapies.

Full Bio
About Us
Our NK Cells
Bladder Program
Multiple Myeloma
News & Media
Contact Us
Investor Hub

Rob Lewis

Chief Executive Officer | NOK Therapeutics

rlewis@noktx.com

Rob Lewis, co-founder of NOK Therapeutics, has served as the company’s Chief Executive Officer and Director since June 2024. With nearly three decades of experience in the pharmaceutical industry, Rob began his career at TEVA Pharmaceuticals and has held leadership roles at global and mid-tier companies such as Sigma and Cypress Pharmaceuticals. His extensive expertise spans Scientific Affairs, Medical Affairs, Regulatory Affairs, Clinical Affairs, and International and Domestic Business Development. Over his career, Rob has overseen 30 NDA and ANDA FDA drug approvals and successfully led numerous product launches. Since 2012, he has been an entrepreneur, co-founding and taking ownership stakes in multiple biotech, pharmaceutical, and medical device companies, while serving on the board of directors for each. Rob earned his Bachelor’s Degree in Chemistry and Biology from Columbia College.

Tamara Jovonovich, PhD

Chief Operating Officer | NOK Therapeutics

tjovonovich@noktxcom

Tamara Jovonovich brings over two decades of experience in pharmaceutical research, development, and leadership to her role as COO of NOK Therapeutics. She earned dual Bachelor of Science degrees in Chemistry and Fine Arts from the University of Central Florida in 1996, followed by a Ph.D. in Biophysical Chemistry from the University of Washington in 2000. Tamara further honed her expertise through post-doctoral research at Stanford University and served as a lecturer at San Jose State University before transitioning to the pharmaceutical industry in Palo Alto, CA, in 2004. Since then, she has held key positions at start-up and medium-cap pharmaceutical companies, including Alexza Pharmaceuticals, Cypress Pharmaceuticals, and Pernix Therapeutics, where she contributed to advancing innovative therapies and building successful teams.